Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.

Gamida Cell's Omisirge made it to the US market at the end of last year but despite a better-than-expected launch, the Israeli group has been forced to explore strategic alternatives to survive.

Troubled by recent clinical disappointments, First Wave will combine with ImmunogenX to focus on that company’s Phase III-ready enzyme replacement therapy for celiac disease. A deep-pocketed partner waits in the wings.

The three-day meeting in Carlsbad, CA, included commentary from numerous executives and investors in the cell and gene therapy space. Here are some of the biggest takeaways.